Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Pieris Pharmaceuticals Inc is a biotechnology business based in the US. Pieris Pharmaceuticals shares (PIRS) are listed on the NASDAQ and all prices are listed in US Dollars. Pieris Pharmaceuticals employs 111 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$4.32|
|52-week range||$1.70 - $6.15|
|50-day moving average||$5.25|
|200-day moving average||$3.65|
|Wall St. target price||$8.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.85|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-4.21%|
|1 month (2021-09-24)||-23.13%|
|3 months (2021-07-23)||28.19%|
|6 months (2021-04-23)||89.47%|
|1 year (2020-10-23)||92.00%|
|2 years (2019-10-23)||35.85%|
|3 years (2018-10-23)||4.78|
|5 years (2016-10-21)||166.67%|
|Revenue TTM||$23.7 million|
|Gross profit TTM||$-14,814,000|
|Return on assets TTM||-21.64%|
|Return on equity TTM||-103.55%|
|Market capitalisation||$300.9 million|
TTM: trailing 12 months
There are currently 1.1 million Pieris Pharmaceuticals shares held short by investors – that's known as Pieris Pharmaceuticals's "short interest". This figure is 2.1% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting Pieris Pharmaceuticals shares can be evaluated.
Pieris Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Pieris Pharmaceuticals shares currently shorted divided by the average quantity of Pieris Pharmaceuticals shares traded daily (recently around 2.0 million). Pieris Pharmaceuticals's SIR currently stands at 0.55. In other words for every 100,000 Pieris Pharmaceuticals shares traded daily on the market, roughly 550 shares are currently held short.
However Pieris Pharmaceuticals's short interest can also be evaluated against the total number of Pieris Pharmaceuticals shares, or, against the total number of tradable Pieris Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pieris Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Pieris Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0201% of the tradable shares (for every 100,000 tradable Pieris Pharmaceuticals shares, roughly 20 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pieris Pharmaceuticals.
Find out more about how you can short Pieris Pharmaceuticals stock.
We're not expecting Pieris Pharmaceuticals to pay a dividend over the next 12 months.
Pieris Pharmaceuticals's shares were split on a 25:11 basis on 7 December 2014. So if you had owned 11 shares the day before before the split, the next day you'd have owned 25 shares. This wouldn't directly have changed the overall worth of your Pieris Pharmaceuticals shares – just the quantity. However, indirectly, the new 56% lower share price could have impacted the market appetite for Pieris Pharmaceuticals shares which in turn could have impacted Pieris Pharmaceuticals's share price.
Over the last 12 months, Pieris Pharmaceuticals's shares have ranged in value from as little as $1.7 up to $6.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pieris Pharmaceuticals's is 1.2021. This would suggest that Pieris Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Pieris Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers and develops anticalin protein-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-expressing solid tumors. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein targeting 4-1BB and PD-L1 for immuno-oncology diseases; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc. ; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.